Blood Fibrocytes During an Exacerbation and Lung Function Decline in Patients With COPD in Primary Care.

Overview

This study aims to estimate the association between blood fibrocytes measured during a suspected exacerbation and 3-year decline forced expiratory volume in one second (FEV1), in patients with Chronic obstructive pulmonary disease (COPD) in primary care, with a history of smoking, independently of the number of exacerbations and of tobacco or occupational exposure.

Full Title of Study: “Association Between Blood Fibrocytes During an Exacerbation and Lung Function Decline in Patients With Early Stage Chronic Obstructive Pulmonary Disease (COPD) in Primary Care”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 1, 2020

Detailed Description

COPD is highly prevalent in primary care. It is associated with tobacco smoke or toxic occupational exposure. Some COPD patients will experience a faster decline in quality of life and lung function. There is currently no prognostic marker allowing to identify those patients at higher risk of fast lung function decline. Recent data suggest that fibrocytes are involved in COPD's physiopathology. A higher blood fibrocytes level during an acute exacerbation has been associated with higher mortality in COPD patients at a late stage of the disease. In mice, fibrocytes role in lung function decline has been demonstrated at an early stage. To date, association between blood fibrocytes during an exacerbation and lung function decline has not been evaluated at the early stage of COPD in humans. This study aims to estimate the association between blood fibrocytes measured during a suspected exacerbation and 3-year decline in forced expiratory volume in one second (FEV1), in patients with COPD in primary care, with a history of smoking, independently of the number of exacerbations and of tobacco or occupational exposure. In this study, blood fibrocytes during a suspected exacerbation will be measured at inclusion. The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion. COPD-related health status and severity of dyspnea will be assessed with COPD Assessment test (CAT) and the modified Medical Research Council dyspnea scale (mMRC) at follow-up visits at 2 months, 12 months and 36 months after inclusion.

Interventions

  • Diagnostic Test: spirometry
    • The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.

Arms, Groups and Cohorts

  • COPD exacerbation
    • COPD exacerbation, compared according to blood fibrocytes level measured during the suspected exacerbation (Day 1)

Clinical Trial Outcome Measures

Primary Measures

  • number of blood fibrocytes
    • Time Frame: Day 1
    • blood fibrocytes level measured during the suspected exacerbation
  • Forced Expiratory Volume (FEV)
    • Time Frame: month 36
    • FEV1 assessed by spirometry

Secondary Measures

  • Forced Expiratory Volume (FEV)
    • Time Frame: month 2
    • FEV1 assessed by spirometry
  • Forced Expiratory Volume (FEV)
    • Time Frame: month 12
    • FEV1 assessed by spirometry
  • Score of modified Medical Research Council dyspnea scale
    • Time Frame: month 2
    • The MMRC dyspnea scale is a standardized questionnaire validated and measuring the degree of dyspnea in patients with COPD. The scale is an ordinal variable into 5 classes from 0 to 4, a score of 4 representing a major dyspnea.
  • Score of modified Medical Research Council dyspnea scale
    • Time Frame: month 12
    • The MMRC dyspnea scale is a standardized questionnaire validated and measuring the degree of dyspnea in patients with COPD. The scale is an ordinal variable into 5 classes from 0 to 4, a score of 4 representing a major dyspnea.
  • Score of modified Medical Research Council dyspnea scale
    • Time Frame: month 36
    • The MMRC dyspnea scale is a standardized questionnaire validated and measuring the degree of dyspnea in patients with COPD. The scale is an ordinal variable into 5 classes from 0 to 4, a score of 4 representing a major dyspnea.
  • Score of Chronic obstructive pulmonary disease Assessment Test
    • Time Frame: month 2
    • health status measured by CAT (http://www.catestonline.org/english/index_France.htm)
  • Score of Chronic obstructive pulmonary disease Assessment Test
    • Time Frame: month 12
    • health status measured by CAT (http://www.catestonline.org/english/index_France.htm)
  • Score of Chronic obstructive pulmonary disease Assessment Test
    • Time Frame: month 36
    • health status measured by CAT (http://www.catestonline.org/english/index_France.htm)

Participating in This Clinical Trial

Inclusion Criteria

  • man or woman aged more than 40 years old, – with tobacco exposure of more than 20 pack-years, – Presenting to a General Practitioner with a suspected mild or moderate COPD exacerbation according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (worsening of symptoms with the need for prescribing short acting bronchodilatators, antibiotics or oral corticosteroids) – Informed consent given – Affiliated to a social insurance scheme Exclusion Criteria:

  • Severe exacerbation of COPD according to GOLD guidelines (patient requires hospitalization or visits to the emergency room), – More likely differential diagnosis than a COPD exacerbation, such as pneumonia, acute pulmonary oedema or other differential diagnosis, – history of asthma, pulmonary fibrosis, primary pulmonary hypertension or chronic viral infections (HIV, hepatitis) – person under care or protection of vulnerable adults

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Bordeaux
  • Collaborator
    • Institut National de la Santé Et de la Recherche Médicale, France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Emmanuel Prothon, MD, Principal Investigator, University of Bordeaux
    • Patrick Berger, MD/PhD, Study Chair, Hospital University, Bordeaux
  • Overall Contact(s)
    • Emmanuel Prothon, MD, +33662539394, emmanuel.prothon@u-bordeaux.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.